Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diflucortolone valerate. Asian experience.

G Hoppe1

  • 1Far East Scientific Office and Clinical Research Centre, Makati, Manila, Philippines.

Drugs
|January 1, 1988
PubMed
Summary

Diflucortolone valerate demonstrates significant efficacy and tolerability in various dermatological conditions. Clinical trials confirm its value as a potent topical corticosteroid, both alone and in combination therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prenatal adversity: a risk factor in borderline personality disorder?

Psychological medicine·2012
Same author

Accumulation of oxidized lipid-protein complexes alters phagosome maturation in retinal pigment epithelium.

Cellular and molecular life sciences : CMLS·2004
Same author

Oxidized low density lipoprotein-induced inhibition of processing of photoreceptor outer segments by RPE.

Investigative ophthalmology & visual science·2001
Same author

Macrophage receptors responsible for distinct recognition of low density lipoprotein containing pyrrole or pyridinium adducts: models of oxidized low density lipoprotein.

Journal of lipid research·2000
Same author

Non-conventional modification of low density lipoproteins: chemical models for macrophage recognition of oxidized LDL.

Biochimica et biophysica acta·1998
Same author

Oxidation products of cholesteryl linoleate are resistant to hydrolysis in macrophages, form complexes with proteins, and are present in human atherosclerotic lesions.

Journal of lipid research·1997

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Diflucortolone valerate was introduced over a decade ago in Germany and Asian countries.
  • It is available in 0.1% and 0.3% concentrations in various topical formulations.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of diflucortolone valerate in different dermatological conditions.
  • To assess the effectiveness of diflucortolone valerate in combination with other agents.

Main Methods:

  • Multicentre trials involving over 897 patients initially, with follow-up trials including up to 1295 patients.
  • Randomised double-blind trials comparing diflucortolone valerate formulations against other treatments.

Main Results:

  • Good efficacy, tolerability, and rapid onset of action were observed in initial trials.
  • Combination therapies showed excellent results, with diflucortolone valerate demonstrating superior efficacy in infected skin conditions compared to a broad-spectrum combination.
  • The 0.3% concentration proved highly effective for severe, resistant skin diseases with a low side-effect profile.
  • A combination with isoconazole nitrate showed significantly better results for dermatomycosis than clotrimazole alone.

Conclusions:

  • Diflucortolone valerate is a valuable therapeutic agent in dermatology.
  • Its efficacy is well-established in various galenic bases and combination therapies.

Related Experiment Videos